Tempest Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13

TL;DR

<b>Tempest Therapeutics will hold its virtual Annual Meeting of Stockholders on June 13, 2024, to elect directors, approve executive compensation, and ratify auditor selection.</b>

AI Summary

Tempest Therapeutics, Inc. (TPST) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Annual Meeting of Stockholders to be held virtually on June 13, 2024, at 1:00 PM Pacific Time. Key agenda items include election of directors Stephen Brady, Michael Raab, and Ronit Simantov. Stockholders will vote on an advisory basis for named executive officer compensation. The selection of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified. The record date for determining stockholders eligible to vote is April 18, 2024.

Why It Matters

For investors and stakeholders tracking Tempest Therapeutics, Inc., this filing contains several important signals. The election of directors and advisory vote on executive compensation are standard governance procedures that allow shareholders to influence company leadership and pay practices. Ratifying the independent auditor is crucial for maintaining financial transparency and investor confidence in the company's financial reporting.

Risk Assessment

Risk Level: low — Tempest Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Review the director nominees and executive compensation proposals to inform voting decisions at the upcoming Annual Meeting.

Key Numbers

• June 13, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• 1:00 PM Pacific Time — Annual Meeting Time (Time of the Annual Meeting of Stockholders)
• April 18, 2024 — Record Date (Date to determine stockholder eligibility to vote)
• 2027 — Director Term End (Year until elected directors will hold office)

Key Players & Entities

• Tempest Therapeutics, Inc. (company) — Registrant
• Stephen Brady (person) — Director nominee
• Michael Raab (person) — Director nominee
• Ronit Simantov (person) — Director nominee
• Ernst & Young LLP (company) — Independent registered public accounting firm
• June 13, 2024 (date) — Annual Meeting date
• April 18, 2024 (date) — Record date for Annual Meeting
• 2027 (date) — Term for elected directors

FAQ

Industry Context

Tempest Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel therapies.

Regulatory Implications

The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring specific disclosures for shareholder meetings.

What Investors Should Do

1. Review the biographies and qualifications of the director nominees: Stephen Brady, Michael Raab, and Ronit Simantov.
2. Evaluate the advisory resolution on executive compensation to understand the company's pay practices for its named executive officers.
3. Confirm the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2024.

Key Dates

• 2024-06-13: Annual Meeting of Stockholders — To elect directors, approve executive compensation, and ratify auditor selection.
• 2024-04-18: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine proxy statement for an annual meeting and does not provide comparative financial data from a previous filing.

Filing Documents

• d240250ddef14a.htm (DEF 14A) — 372KB
• g240250dsp041.jpg (GRAPHIC) — 4KB
• g240250dsp041a.jpg (GRAPHIC) — 2KB
• g240250g00r78.jpg (GRAPHIC) — 29KB
• g240250g16m01.jpg (GRAPHIC) — 20KB
• g240250g16m02.jpg (GRAPHIC) — 46KB
• g240250g16m03.jpg (GRAPHIC) — 44KB
• g240250g33m01.jpg (GRAPHIC) — 79KB
• g240250g33m03.jpg (GRAPHIC) — 79KB
• 0001193125-24-106959.txt (&nbsp;) — 790KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 34 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION 36 OTHER INFORMATION FOR STOCKHOLDERS 37 OTHER MATTERS 38 Website References You may also access additional information about Tempest Therapeutics, Inc. at www.tempesttx.com and ir.tempesttx.com . References to our websites throughout this proxy statement are provided for convenience only and the content on our website does not constitute a part of this proxy statement. Table of Contents PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 13, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the SEC ), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the Notice ) because the Board of Directors (the Board ) of Tempest Therapeutics, Inc. (the Company or Tempest ) is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the Annual Meeting ), including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 24, 2024 to all stockholders of record entitled to vote at the Annual Meeting. Will I receive any other proxy materials by mail? You will not receive any additional proxy materials via mail unless you request a printed copy in accordance with the instructions set forth in the Notice. We may elect to send you a proxy card, along with a second Notice, aft

View Full Filing

View this DEF 14A filing on SEC EDGAR